A quantitative GFP-based bioassay for the detection of HIV-1 Tat transactivation inhibitors

Dirk Daelemans; De Clercq Erik; Anne‐Mieke Vandamme

doi:10.1016/s0166-0934(01)00330-5

Related publications

Article2017

Quantitative proteomic analysis of HIV‐1 Tat‐induced dysregulation in SH‐SY5Y neuroblastoma cells

Tariq Ganief, Putuma P. Gqamana, Shaun Garnett, Jacqueline Hoare, Dan Joseph Stein, John A. Joska, Nelson C. Soares, Jonathan M. Blackburn

Article2003

Discovery of a Tat HIV‐1 Inhibitor through Computer‐Aided Drug Design

Didier Esquieu, Jean‐Marie Péloponèse, Sandrine Opi, Catherine Grégoire, Jean de Mareuil, Jennifer Watkins, Grant R. Campbell, Jean-Pierre Dunot, James N. Sturgis, Myriam Witvrouw, Christophe Pannecouque, De Clercq Erik, Mickaël Montembault, Giang Vo‐Thanh, Monique Villiéras, Valérie Fargeas, Jacques Lebreton, Erwann Loret

Article1995

Quantitative structural activity relationship study of bis-tetraazacyclic compounds. A novel series of HIV-1 and HIV-2 inhibitors

Heidi C. João, K De Vreese, Rudi Pauwels, De Clercq Erik, Geoff W. Henson, Gary Bridger

Article2013

Design, Synthesis and Biological Evaluation of Substituted Guanidine Indole Derivatives as Potential Inhibitors of HIV-1 Tat-TAR Interaction

Jun Wang, Yan Wang, Zhenyu Li, Peng Zhan, Ru-Jun Bai, Christophe Pannecouque, Jan Balzarini, De Clercq Erik, Xinyong Liu

Article2003

Assays for the Evaluation of HIV-1 Integrase Inhibitors

Zeger Debyser, Peter Cherepanov, Wim Pluymers, De Clercq Erik